Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase

A compound of formula (I)

• 12
• wherein:
• X represents H, C1 to 4 alkyl, C1 to 4 alkoxy, halogen, OH, NHR9, CN, C≡CH, NO2, CHO, COCH3 or NHCHO;
• said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms or by an OH group;
• Y represents C1 to 4 alkyl, C1 to 4 alkoxy, halogen, OH, CN, C≡CH, NO2, CHO, COCH3 or NHCHO;
• said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;
• One of T, U and W represents N and the other two independently represent CR4;
• and each R4 group independently represents H, F or CH3;
• V represents O or S(O)n;
• n represents an integer 0, 1 or 2;
• Q represents CH2 or (CH2)2;
• R1 represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N;
• said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from halogen, C1 to 4 alkyl, C1 to 4 alkoxy, OH, CN, NO2 or NR5R6;
• said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;
• R2 and R3 independently represent H, C1 to 4 alkyl or C3 to 6 cycloalkyl;
• said alkyl group being optionally substituted by C1 to 4 alkoxy, halogen, hydroxy, —Z—NR7 R8, phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N;
• said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF3, OCF3, OH, CN or NO2;
• Z represents —CO— or a bond;
• R5, R6, R7 and R8 independently represent H or C1 to 4 alkyl;
• R9 represents H or C1 to 4 alkyl;
• said alkyl being optionally further substituted by one or more fluorine atoms;
• or a pharmaceutically acceptable salt thereof.